Matches in Wikidata for { <http://www.wikidata.org/entity/Q92672503> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- Q92672503 description "2019 թվականի հունիսի 11-ին հրատարակված գիտական հոդված" @default.
- Q92672503 description "article scientifique publié en 2019" @default.
- Q92672503 description "artículu científicu espublizáu en xunu de 2019" @default.
- Q92672503 description "bài báo khoa học" @default.
- Q92672503 description "im Juni 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92672503 description "scientific article published on 11 June 2019" @default.
- Q92672503 description "wetenschappelijk artikel" @default.
- Q92672503 description "наукова стаття, опублікована 11 червня 2019" @default.
- Q92672503 name "Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series" @default.
- Q92672503 name "Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series" @default.
- Q92672503 type Item @default.
- Q92672503 label "Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series" @default.
- Q92672503 label "Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series" @default.
- Q92672503 prefLabel "Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series" @default.
- Q92672503 prefLabel "Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series" @default.
- Q92672503 P1433 Q92672503-E94FE3BA-084E-4AD6-A137-57499F910277 @default.
- Q92672503 P1476 Q92672503-7645B42D-39DE-4648-B2E4-D63F21B2C09A @default.
- Q92672503 P2093 Q92672503-16E9B724-D81F-42E4-BB37-9DFC1238B035 @default.
- Q92672503 P2093 Q92672503-2463EBE7-FB85-4F7E-877D-AD734B9B9FF7 @default.
- Q92672503 P2093 Q92672503-2A82D7B0-AF94-4764-B85C-B2F7A4A62D44 @default.
- Q92672503 P2093 Q92672503-2F3EAC90-2911-41E9-9207-F2AA4BED674B @default.
- Q92672503 P2093 Q92672503-2F49C8A0-779A-4BD7-A5A6-1734F5331B17 @default.
- Q92672503 P2093 Q92672503-3AD5E0F9-E83D-4650-8555-C3DBBE90C98E @default.
- Q92672503 P2093 Q92672503-6782D5AD-DFC7-46B0-944B-027D4717D1A1 @default.
- Q92672503 P2093 Q92672503-856AE509-71F3-4582-847B-1CE6CDD21011 @default.
- Q92672503 P2093 Q92672503-879967C0-ECDA-45DD-8147-9805D67D4620 @default.
- Q92672503 P2093 Q92672503-DD15F856-D41D-4AC3-A020-343D4FC6BEE6 @default.
- Q92672503 P2093 Q92672503-FAD7204C-F3E7-47EC-B313-FBB3A44DB727 @default.
- Q92672503 P304 Q92672503-C1F23380-A544-4777-BEAB-A55DF63CAEF5 @default.
- Q92672503 P31 Q92672503-0DCD86C9-EB6D-4308-9DAC-0FDAEB4E9128 @default.
- Q92672503 P356 Q92672503-0A3F14A5-1B44-43C7-8CD4-3FB7D6967850 @default.
- Q92672503 P433 Q92672503-E5DAB12C-DAAC-4B6A-8C41-B39564F79C0E @default.
- Q92672503 P478 Q92672503-8D76DB49-84CC-459B-90BB-B2B8F0A6DDCC @default.
- Q92672503 P50 Q92672503-B5FD70BE-6E5C-4A73-90CD-6FC0F738C96A @default.
- Q92672503 P577 Q92672503-96D11F48-F8C3-4997-A035-78FDF33AEC61 @default.
- Q92672503 P698 Q92672503-492AB809-DA49-4C5D-B561-71072634D878 @default.
- Q92672503 P356 S00259-019-04389-2 @default.
- Q92672503 P698 31187162 @default.
- Q92672503 P1433 Q15708890 @default.
- Q92672503 P1476 "Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series" @default.
- Q92672503 P2093 "Amir Iravani" @default.
- Q92672503 P2093 "Aravind S Ravi Kumar" @default.
- Q92672503 P2093 "David Westerman" @default.
- Q92672503 P2093 "Grace Kong" @default.
- Q92672503 P2093 "Ing S Tiong" @default.
- Q92672503 P2093 "Isaac Goncalves" @default.
- Q92672503 P2093 "Kate Burbury" @default.
- Q92672503 P2093 "Michael Michael" @default.
- Q92672503 P2093 "Piers Blombery" @default.
- Q92672503 P2093 "Rodney J Hicks" @default.
- Q92672503 P2093 "Tim Akhurst" @default.
- Q92672503 P304 "1902-1910" @default.
- Q92672503 P31 Q13442814 @default.
- Q92672503 P356 "10.1007/S00259-019-04389-2" @default.
- Q92672503 P433 "9" @default.
- Q92672503 P478 "46" @default.
- Q92672503 P50 Q53198887 @default.
- Q92672503 P577 "2019-06-11T00:00:00Z" @default.
- Q92672503 P698 "31187162" @default.